Use of therapeutic plasma exchange to remove lipoprotein X in a patient with vanishing bile duct syndrome presenting with cholestasis, pseudohyponatremia, and hypercholesterolemia: A case report and review of literature

Abstract Introduction Lipoprotein X (Lp‐X) is an abnormal lipoprotein found in multiple disease conditions, including liver dysfunction and cholestasis. High Lp‐X concentrations can interfere with some laboratory testing that may result in spurious results. The detection of Lp‐X can be challenging, and there is currently a lack of consensus regarding the management of Lp‐X other than treating the underlying disease. Case Presentation A 42‐year‐old female with Hodgkin's lymphoma treated with dexamethasone, high dose cytarabine and cisplatin and vanishing bile duct syndrome confirmed by liver biopsy presented with cholestasis, pseudohyponatremia (sodium, 113 mmol/L; reference range 136–146 mmL/L; serum osmolality, 303 mOsm/kg), and hypercholesterolemia (> 2800 mg/dL, reference range < 200 mg/dL). Lp‐X was confirmed by lipoprotein electrophoresis (EP). Although she did not manifest any specific signs or symptoms, therapeutic plasma exchange (TPE) was initiated based on laboratory findings of extreme hypercholesterolemia, spuriously abnormal serum sodium, and HDL values, and the potential for short‐ and long‐term sequelae such as hyperviscosity syndrome, xanthoma, and neuropathy. During the hospitalization, she was treated with four 1.0 plasma volume TPE over 6 days using 5% albumin for replacement fluid. After the first TPE, total cholesterol (TC) decreased to 383 mg/dL and sodium was measured at 131 mmol/L. The patient was transitioned into outpatient maintenance TPE to eliminate the potential of Lp‐X reappearance while the underlying disease was treated. Serial follow‐up laboratory testing with lipoprotein EP showed the disappearance of Lp‐X after nine TPEs over a 10‐week period. Literature Review There are seven and four case reports of Lp‐X treated with TPE and lipoprotein apheresis (LA), respectively. While all previous case reports showed a reduction in TC levels, none had monitored the disappearance of Lp‐X after completing a course of therapeutic apheresis. Conclusion Clinicians should have a heightened suspicion for the presence of abnormal Lp‐X in patients with cholestasis, hypercholesterolemia, and pseudohyponatremia. Once Lp‐X is confirmed by lipoprotein EP, TPE should be initiated to reduce TC level and remove abnormal Lp‐X. Most LA techniques are not expected to be beneficial since Lp‐X lacks apolipoprotein B. Therefore, we suggest that inpatient course of TPE be performed every other day until serum sodium, TC and HDL levels become normalized. Outpatient maintenance TPE may also be considered to keep Lp‐X levels low while the underlying disease is treated. Serum sodium, TC, and HDL levels should be monitored while on maintenance TPE.